Production (Stage)
Zevra Therapeutics, Inc.
ZVRA
$8.65
$0.080.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.59M | 23.61M | 24.49M | 23.69M | 27.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.59M | 23.61M | 24.49M | 23.69M | 27.71M |
| Cost of Revenue | 8.59M | 7.42M | 7.28M | 5.12M | 2.22M |
| Gross Profit | 32.00M | 16.20M | 17.21M | 18.57M | 25.49M |
| SG&A Expenses | 64.53M | 54.92M | 54.18M | 43.79M | 37.79M |
| Depreciation & Amortization | 6.32M | 6.24M | 5.39M | 3.85M | 2.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.47M | 110.62M | 111.23M | 98.49M | 84.97M |
| Operating Income | -71.88M | -87.00M | -86.74M | -74.80M | -57.26M |
| Income Before Tax | -75.37M | -90.14M | -89.66M | -66.63M | -49.42M |
| Income Tax Expenses | 16.62M | 15.37M | 0.00 | 177.00K | 33.00K |
| Earnings from Continuing Operations | -91.99 | -105.51 | -89.66 | -66.81 | -49.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.99M | -105.51M | -89.66M | -66.81M | -49.45M |
| EBIT | -71.88M | -87.00M | -86.74M | -74.80M | -57.26M |
| EBITDA | -65.40M | -80.61M | -81.22M | -70.83M | -54.77M |
| EPS Basic | -1.90 | -2.24 | -2.08 | -1.69 | -1.29 |
| Normalized Basic EPS | -0.99 | -1.22 | -1.30 | -1.05 | -0.81 |
| EPS Diluted | -1.90 | -2.24 | -2.08 | -1.69 | -1.29 |
| Normalized Diluted EPS | -0.99 | -1.22 | -1.30 | -1.05 | -0.81 |
| Average Basic Shares Outstanding | 197.28M | 184.96M | 170.20M | 157.12M | 149.12M |
| Average Diluted Shares Outstanding | 197.28M | 184.96M | 170.20M | 157.12M | 149.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |